A citation-based method for searching scientific literature


List of co-cited articles
140 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
52

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
41

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
35

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
35

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
716
29


Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
531
23

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
David R Powell, Melinda Smith, Jennifer Greer, Angela Harris, Sharon Zhao, Christopher DaCosta, Faika Mseeh, Melanie K Shadoan, Arthur Sands, Brian Zambrowicz,[...]. J Pharmacol Exp Ther 2013
131
23

Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
824
23

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
425
17

Chylomicrons stimulate incretin secretion in mouse and human cells.
Arianna Psichas, Pierre F Larraufie, Deborah A Goldspink, Fiona M Gribble, Frank Reimann. Diabetologia 2017
37
17

Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine.
Louise W Christensen, Rune E Kuhre, Charlotte Janus, Berit Svendsen, Jens J Holst. Physiol Rep 2015
71
17

Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors.
Cheryl A Brighton, Juraj Rievaj, Rune E Kuhre, Leslie L Glass, Kristina Schoonjans, Jens J Holst, Fiona M Gribble, Frank Reimann. Endocrinology 2015
196
17

Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium.
Fiona M Gribble, Frank Reimann. Annu Rev Physiol 2016
286
17

Chylomicron formation and secretion is required for lipid-stimulated release of incretins GLP-1 and GIP.
Wendell J Lu, Qing Yang, Li Yang, Dana Lee, David D'Alessio, Patrick Tso. Lipids 2012
37
17

Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
Timo Rieg, Takahiro Masuda, Maria Gerasimova, Eric Mayoux, Kenneth Platt, David R Powell, Scott C Thomson, Hermann Koepsell, Volker Vallon. Am J Physiol Renal Physiol 2014
172
17

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
Meg J Jardine, Kenneth W Mahaffey, Bruce Neal, Rajiv Agarwal, George L Bakris, Barry M Brenner, Scott Bull, Christopher P Cannon, David M Charytan, Dick de Zeeuw,[...]. Am J Nephrol 2017
148
17


Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li,[...]. Circulation 2018
293
17

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
536
17

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
396
17

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink. Diabetes Obes Metab 2018
136
17


Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
17



Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
505
11

Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.
Tomohide Hayami, Yoshiro Kato, Hideki Kamiya, Masaki Kondo, Ena Naito, Yukako Sugiura, Chika Kojima, Sami Sato, Yuichiro Yamada, Rina Kasagi,[...]. J Diabetes Investig 2015
77
11

The incretin system and its role in type 2 diabetes mellitus.
Jens Juul Holst, Tina Vilsbøll, Carolyn F Deacon. Mol Cell Endocrinol 2009
352
11

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. Biopharm Drug Dispos 2014
201
11

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
145
11

Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers.
T E Adrian, S Gariballa, K A Parekh, S A Thomas, H Saadi, J Al Kaabi, N Nagelkerke, B Gedulin, A A Young. Diabetologia 2012
96
11

Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
Mark Ellrichmann, Mario Kapelle, Peter R Ritter, Jens J Holst, Karl-Heinz Herzig, Wolfgang E Schmidt, Frank Schmitz, Juris J Meier. J Clin Endocrinol Metab 2008
61
11

Metformin and the gastrointestinal tract.
Laura J McCreight, Clifford J Bailey, Ewan R Pearson. Diabetologia 2016
329
11


Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.
Gwen Tolhurst, Helen Heffron, Yu Shan Lam, Helen E Parker, Abdella M Habib, Eleftheria Diakogiannaki, Jennifer Cameron, Johannes Grosse, Frank Reimann, Fiona M Gribble. Diabetes 2012
11

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
M S Svane, N B Jørgensen, K N Bojsen-Møller, C Dirksen, S Nielsen, V B Kristiansen, S Toräng, N J Wewer Albrechtsen, J F Rehfeld, B Hartmann,[...]. Int J Obes (Lond) 2016
110
11



Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution.
Filip K Knop, Tina Vilsbøll, Steen Larsen, Patricia V Højberg, Aage Vølund, Sten Madsbad, Jens J Holst, Thure Krarup. Am J Physiol Endocrinol Metab 2007
74
11

Gut Hormone Regulation and Secretion via FFA1 and FFA4.
Fiona M Gribble, Eleftheria Diakogiannaki, Frank Reimann. Handb Exp Pharmacol 2017
19
11

Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.
Nils B Jørgensen, Carsten Dirksen, Kirstine N Bojsen-Møller, Siv H Jacobsen, Dorte Worm, Dorte L Hansen, Viggo B Kristiansen, Lars Naver, Sten Madsbad, Jens J Holst. Diabetes 2013
202
11


Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
297
11

Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
M Hansen, M J Scheltema, D P Sonne, J S Hansen, M Sperling, J F Rehfeld, J J Holst, T Vilsbøll, F K Knop. Diabetes Obes Metab 2016
59
11

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
David Polidori, Sue Sha, Sunder Mudaliar, Theodore P Ciaraldi, Atalanta Ghosh, Nicole Vaccaro, Kristin Farrell, Paul Rothenberg, Robert R Henry. Diabetes Care 2013
189
11

Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans.
T Wu, M J Bound, S D Standfield, B Gedulin, K L Jones, M Horowitz, C K Rayner. Diabetes Obes Metab 2013
88
11

Generation of L cells in mouse and human small intestine organoids.
Natalia Petersen, Frank Reimann, Sina Bartfeld, Henner F Farin, Femke C Ringnalda, Robert G J Vries, Stieneke van den Brink, Hans Clevers, Fiona M Gribble, Eelco J P de Koning. Diabetes 2014
90
11


Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
Jerry R Greenfield, I Sadaf Farooqi, Julia M Keogh, Elana Henning, Abdella M Habib, Anthea Blackwood, Frank Reimann, Jens J Holst, Fiona M Gribble. Am J Clin Nutr 2009
166
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.